Erika J Starks1, J Patrick O'Grady1, Siobhan M Hoscheidt1, Annie M Racine1, Cynthia M Carlsson1,2, Henrik Zetterberg3,4, Kaj Blennow3,5, Ozioma C Okonkwo1,6, Luigi Puglielli1,2, Sanjay Asthana1,2, N Maritza Dowling1,7, Carey E Gleason1,2, Rozalyn M Anderson2, Nancy J Davenport-Sis1, LeAnn M DeRungs1, Mark A Sager1,6, Sterling C Johnson1,2,6, Barbara B Bendlin1,6. 1. Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. 2. Geriatric Research Education and Clinical Center, Wm. S. Middleton Memorial Veterans Hospital, Madison, WI, USA. 3. Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden. 4. UCL Institute of Neurology, Queen Square, London, UK. 5. The Torsten Söderberg Professorship at the Royal Swedish Academy of Sciences, Sweden. 6. Wisconsin Alzheimer's Institute, Wisconsin School of Medicine and Public Health, Madison, WI, USA. 7. Department of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Abstract
BACKGROUND: Insulin resistance (IR) is linked with the occurrence of pathological features observed in Alzheimer's disease (AD), including neurofibrillary tangles and amyloid plaques. However, the extent to which IR is associated with AD pathology in the cognitively asymptomatic stages of preclinical AD remains unclear. OBJECTIVE: To determine the extent to which IR is linked with amyloid and tau pathology in late-middle-age. METHOD: Cerebrospinal fluid (CSF) samples collected from 113 participants enrolled in the Wisconsin Registry for Alzheimer's Prevention study (mean age = 60.6 years), were assayed for AD-related markers of interest: Aβ₄₂, P-Tau181, and T-Tau. IR was determined using the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR). Linear regression was used to test the effect of IR, and APOEɛ4, on tau and amyloid pathology. We hypothesized that greater IR would be associated with higher CSF P-Tau181 and T-Tau, and lower CSF Aβ₄₂. RESULTS: No significant main effects of HOMA-IR on P-Tau181, T-Tau, or Aβ₄₂ were observed; however, significant interactions were observed between HOMA-IR and APOEɛ4 on CSF markers related to tau. Among APOEɛ4 carriers, higher HOMA-IR was associated with higher P-Tau181 and T-Tau. Among APOEɛ4 non-carriers, HOMA-IR was negatively associated with P-Tau181 and T-Tau. We found no effects of IR on Aβ₄₂ levels in CSF. CONCLUSION: IR among asymptomatic APOEɛ4 carriers was associated with higher P-Tau181 and T-Tau in late-middle age. The results suggest that IR may contribute to tau-related neurodegeneration in preclinical AD. The findings may have implications for developing prevention strategies aimed at modifying IR in mid-life.
BACKGROUND:Insulin resistance (IR) is linked with the occurrence of pathological features observed in Alzheimer's disease (AD), including neurofibrillary tangles and amyloid plaques. However, the extent to which IR is associated with AD pathology in the cognitively asymptomatic stages of preclinical AD remains unclear. OBJECTIVE: To determine the extent to which IR is linked with amyloid and tau pathology in late-middle-age. METHOD: Cerebrospinal fluid (CSF) samples collected from 113 participants enrolled in the Wisconsin Registry for Alzheimer's Prevention study (mean age = 60.6 years), were assayed for AD-related markers of interest: Aβ₄₂, P-Tau181, and T-Tau. IR was determined using the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR). Linear regression was used to test the effect of IR, and APOEɛ4, on tau and amyloid pathology. We hypothesized that greater IR would be associated with higher CSF P-Tau181 and T-Tau, and lower CSF Aβ₄₂. RESULTS: No significant main effects of HOMA-IR on P-Tau181, T-Tau, or Aβ₄₂ were observed; however, significant interactions were observed between HOMA-IR and APOEɛ4 on CSF markers related to tau. Among APOEɛ4 carriers, higher HOMA-IR was associated with higher P-Tau181 and T-Tau. Among APOEɛ4 non-carriers, HOMA-IR was negatively associated with P-Tau181 and T-Tau. We found no effects of IR on Aβ₄₂ levels in CSF. CONCLUSION: IR among asymptomatic APOEɛ4 carriers was associated with higher P-Tau181 and T-Tau in late-middle age. The results suggest that IR may contribute to tau-related neurodegeneration in preclinical AD. The findings may have implications for developing prevention strategies aimed at modifying IR in mid-life.
Entities:
Keywords:
Alzheimer’s disease; apolipoprotein ɛ4; cerebrospinal fluid; glucose; insulin; insulin resistance; tau protein
Authors: Jeffrey M Burns; Robyn A Honea; Eric D Vidoni; Lewis J Hutfles; William M Brooks; Russell H Swerdlow Journal: Biochim Biophys Acta Date: 2011-07-01
Authors: S Craft; S Asthana; G Schellenberg; L Baker; M Cherrier; A A Boyt; R N Martins; M Raskind; E Peskind; S Plymate Journal: Ann N Y Acad Sci Date: 2000-04 Impact factor: 5.691
Authors: Madhav Thambisetty; E Jeffrey Metter; An Yang; Hillary Dolan; Christopher Marano; Alan B Zonderman; Juan C Troncoso; Yun Zhou; Dean F Wong; Luigi Ferrucci; Josephine Egan; Susan M Resnick; Richard J O'Brien Journal: JAMA Neurol Date: 2013-09-01 Impact factor: 18.302
Authors: Andrew P Merluzzi; Cynthia M Carlsson; Sterling C Johnson; Suzanne E Schindler; Sanjay Asthana; Kaj Blennow; Henrik Zetterberg; Barbara B Bendlin Journal: Neurology Date: 2018-06-29 Impact factor: 9.910
Authors: Annie M Racine; Lindsay R Clark; Sara E Berman; Rebecca L Koscik; Kimberly D Mueller; Derek Norton; Christopher R Nicholas; Kaj Blennow; Henrik Zetterberg; Bruno Jedynak; Murat Bilgel; Cynthia M Carlsson; Bradley T Christian; Sanjay Asthana; Sterling C Johnson Journal: J Alzheimers Dis Date: 2016-10-18 Impact factor: 4.472
Authors: Annie M Racine; Rebecca L Koscik; Sara E Berman; Christopher R Nicholas; Lindsay R Clark; Ozioma C Okonkwo; Howard A Rowley; Sanjay Asthana; Barbara B Bendlin; Kaj Blennow; Henrik Zetterberg; Carey E Gleason; Cynthia M Carlsson; Sterling C Johnson Journal: Brain Date: 2016-06-20 Impact factor: 13.501
Authors: Annie M Racine; Andrew P Merluzzi; Nagesh Adluru; Derek Norton; Rebecca L Koscik; Lindsay R Clark; Sara E Berman; Christopher R Nicholas; Sanjay Asthana; Andrew L Alexander; Kaj Blennow; Henrik Zetterberg; Won Hwa Kim; Vikas Singh; Cynthia M Carlsson; Barbara B Bendlin; Sterling C Johnson Journal: Brain Imaging Behav Date: 2019-02 Impact factor: 3.978
Authors: Steven E Arnold; Zoe Arvanitakis; Shannon L Macauley-Rambach; Aaron M Koenig; Hoau-Yan Wang; Rexford S Ahima; Suzanne Craft; Sam Gandy; Christoph Buettner; Luke E Stoeckel; David M Holtzman; David M Nathan Journal: Nat Rev Neurol Date: 2018-01-29 Impact factor: 42.937
Authors: Auriel A Willette; Barbara B Bendlin; Erika J Starks; Alex C Birdsill; Sterling C Johnson; Bradley T Christian; Ozioma C Okonkwo; Asenath La Rue; Bruce P Hermann; Rebecca L Koscik; Erin M Jonaitis; Mark A Sager; Sanjay Asthana Journal: JAMA Neurol Date: 2015-09 Impact factor: 18.302